Introduction {#Sec1}
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Neglect as a consequence of right brain damage has been recognized at least since J. Hughlings Jackson's 1876 case report \[[@CR1]\]. It was later appreciated that impairment in brain functional connectivity and resulting brain network dysfunction ('connectopathy', 'disconnection syndrome') underlies hemispatial neglect, a common sequela of right hemispheric stroke \[[@CR2], [@CR3]\]. A variety of bedside tests have been found useful as a measure of hemispatial neglect, including the Clock-Drawing Test \[[@CR4]\]. The signature pattern of hemispatial neglect seen after right brain damage with the Clock-Drawing Test is a clock face, drawn from memory, lacking numerals in its left half, which has been termed neglect of the left hemispace \[[@CR5]\] (Fig. [1](#Fig1){ref-type="fig"}a).Fig. 1Clock-drawing test **a** immediately before perispinal etanercept, and **b** 30 min after perispinal etanercept

Advanced brain imaging methods, including functional magnetic resonance and positron emission tomography (PET), allow the in vivo assessment of functional connectivity and neuroinflammation, respectively. These imaging methods have expanded our understanding of post-stroke neuroinflammation. A growing body of evidence suggests that stroke may result in persistent global brain inflammation and that neuroinflammation may impair brain functional connectivity \[[@CR2], [@CR3], [@CR6]--[@CR12]\]. Neuroinflammation after stroke involves microglial activation \[[@CR9], [@CR12]\]. Elevated levels of the cytokine tumor necrosis factor (TNF) in the brain have been implicated in a wide range of brain disorders \[[@CR13]\].

Elevated levels of TNF may adversely affect brain network function because TNF's normal physiological roles include its function as a neuromodulator and gliotransmitter that modulates synaptic scaling and synaptic strength, and regulates the tripartite synapse \[[@CR9], [@CR11], [@CR14], [@CR15]\]. Biologics targeting TNF have become one of most widely used therapeutics in modern medicine. One such human therapeutic is etanercept, a recombinant fusion protein that potently and selectively inhibits the biological activity of TNF. In basic science models, etanercept has been found to reduce microglial activation and ameliorate neurological dysfunction \[[@CR7]--[@CR11], [@CR16]\]. More recently, in addition to its ability to rapidly reduce chronic post-stroke neurological dysfunction when administered by perispinal injection, etanercept was shown to improve neurological outcomes in six different experimental models of stroke \[[@CR9], [@CR11], [@CR16]\].

In contrast to its rapid brain effects when injected perispinally, etanercept has difficulty crossing the blood--brain barrier in therapeutic quantities when administered systemically \[[@CR9], [@CR11], [@CR14], [@CR16], [@CR17]\]. To avoid the trauma associated with invasive methods of brain delivery, such as intracerebroventricular injection, a new method of drug delivery was needed to facilitate the use of etanercept for brain disorders \[[@CR9], [@CR11], [@CR14]--[@CR17]\]. Perispinal administration was designed as a novel method to enhance delivery of etanercept and other large molecules to the brain via the cerebrospinal venous system (CSVS) (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR6], [@CR9], [@CR11], [@CR14]--[@CR18]\].

The CSVS consists of the interconnected cerebral and spinal venous systems, a unique, large capacity, essentially valveless venous network within which bi-directional blood flow occurs, including retrograde blood flow from the spinal venous blood into the brain \[[@CR11], [@CR16], [@CR18]\]. Venous drainage of the anatomical region posterior to the spine is accomplished by the external vertebral venous plexus, the most superficial component of the CSVS \[[@CR11], [@CR16], [@CR18]\]. The external vertebral venous plexus drains into the internal vertebral venous plexus, which itself drains, and drains into the cerebral venous system \[[@CR11], [@CR16], [@CR18]\]. Perispinal injection of etanercept delivers etanercept into the catchment area of the external vertebral venous plexus, thereby enabling etanercept to bypass the blood--cerebrospinal fluid barrier and reach the brain \[[@CR6]--[@CR11], [@CR13]--[@CR19]\].

In an animal model, perispinal administration has been shown to rapidly deliver radiolabeled etanercept into the choroid plexus and cerebrospinal fluid using PET (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR17]\].Fig. 2Cerebrospinal venous system. Detail of plate 5 from Breschet \[[@CR26]\].Courtesy of the Sidney Tobinick collection, modified from the original

More recently, in another animal model, perispinal administration of a TNF antibody was shown to deliver the antibody into the choroid plexus and to have favorable brain effects, alleviating the sensory and affective components of neuropathic pain \[[@CR19]\].

Perispinal etanercept is an emerging treatment for chronic, post-stroke neurological dysfunction, that has been used clinically for more than 8 years and is currently the subject of multiple randomized, placebo-controlled trials underway or in development \[[@CR7]--[@CR9], [@CR11], [@CR14]\]. In stroke, the widespread pattern of rapid neurological improvement seen after perispinal etanercept has been attributed to improvement in functional connectivity due to neutralization of excess TNF \[[@CR11]\]. Rapid improvement in clock drawing in a patient with Alzheimer's disease after perispinal etanercept has previously been reported, but improvement in the Clock-Drawing Test in post-stroke patients after perispinal etanercept has not yet been published \[[@CR6]\].

Case Report {#Sec2}
===========

A 59-year-old man presented to the clinic 16 years after a right middle cerebral artery stroke caused malignant cerebral edema and coma for 1 week, requiring decompressive craniectomy and subsequent cranioplasty. The stroke resulted in chronic left hemiparesis; left hemispatial neglect; visuospatial dysfunction; left sensory loss involving his left upper extremity, left rib cage and left lower extremity; left cold allodynia; cognitive dysfunction, including impaired short-term memory and difficulty with calculations; impulsiveness; chronic post-stroke fatigue; and spasticity. He also reported having constant, intractable post-stroke pain every hour of every day for the entire 16 years after his stroke, involving his left shoulder, left forearm, and entire left lower extremity. He required a left ankle foot orthosis and a single-point cane to ambulate.

Immediately prior to treatment, examination revealed a left hemiparesis, left-sided spasticity, left sensory loss involving both the left upper and lower extremities, cold allodynia on the left upper extremity, cognitive dysfunction (Montreal Cognitive Assessment score = 19/30), Fatigue Assessment Scale Score \[[@CR20]\] of 24/50, and chronic left-sided pain (central post-stroke pain) assessed by the patient as 5/10 in severity on a 0--10 scale. Walking 20 meters took 58 s. The Five Times Sit-to-Stand test required 27 s to complete with assist from his right arm. There was prominent left hemispatial neglect, as measured by the Clock-Drawing Test (Fig. [1](#Fig1){ref-type="fig"}a). As standard procedure in our medical practice, a Clock-Drawing Test is administered immediately before and within 30 min after treatment. As part of the Clock-Drawing Test, the patient is verbally instructed to 'draw a big round clock, with all of the numbers on it'. After the clock has been drawn, the patient is then verbally instructed to 'make the clock say 10 past 11'.

After informed consent was obtained, etanercept 25 mg was administered by perispinal injection, followed by Trendelenburg positioning, as previously described \[[@CR10]\]. Within 10 min, the patient reported that his chronic left-sided post-stroke pain was gone. Within 30 min after etanercept administration, the patient reported a complete absence of his chronic left-sided pain, a reduction in spasticity, and improvements in gait, balance, the ability to turn to the left, and the ability to perceive the position of his left foot. A repeat Clock-Drawing Test performed 30 min after perispinal etanercept injection no longer showed left hemispatial neglect (Fig. [1](#Fig1){ref-type="fig"}b). Seventeen days after treatment, the patient reported, by telephone, his neurological improvements had been maintained, with complete absence of pain, absence of allodynia, and improved peripheral vision. His report of reduced fatigue was supported by his Fatigue Assessment Score, which remained reduced by 7 points, measured as 17/50, at both 1 and 2 months after treatment. Eleven months after receiving his single 25 mg dose of perispinal etanercept, the patient reported sustained neurological improvement, when reached by telephone. He specifically reported that his previously chronic and intractable post-stroke pain that had immediately resolved after receiving perispinal etanercept had never returned. A movie file documents this patient's clinical response to perispinal etanercept treatment in more detail (see Online Resource 1, video before and after perispinal etanercept, 16 years after stroke).Fig. 3PET image showing intraventricular delivery of radiolabeled etanercept after perispinal injection. Transverse section of a living rat brain following perispinal extrathecal administration of Cu64-DOTA-etanercept, imaged 5--10 min following perispinal injection. Note enhanced signal in the choroid plexus and cerebrospinal fluid within the cerebral ventricles.Modified from Tobinick et al. \[[@CR17]\], used under the terms of the Creative Commons Attribution License 2.0. *PET* positron emission tomography

We have observed multiple additional patients with left hemispatial neglect and chronic post-stroke neurological dysfunction who have had rapid resolution of left hemispace neglect measured by the Clock-Drawing Test after a single perispinal etanercept injection. In addition, while using perispinal etanercept over the course of nearly 9 years, we have observed many patients experience immediate improvement in central post-stroke pain after perispinal etanercept, and have previously discussed the scientific rationale for this result \[[@CR7]--[@CR11]\].

Discussion and Conclusions {#Sec3}
==========================

Evidence that perispinal etanercept had the potential to improve chronic brain dysfunction was first published in 2006 \[[@CR15]\]. The first report of rapid improvement in chronic post-stroke neurological dysfunction following perispinal etanercept was published in 2011 \[[@CR7]\]. A 2012 observational study involving 617 patients treated with perispinal etanercept for chronic post-stroke neurological dysfunction included mention of a single patient with improvement in hemispatial neglect, beginning 2 h after perispinal etanercept was administered, but changes in clock drawing were not reported \[[@CR8]\]. This is the first report and documentation of immediate improvement in hemispatial neglect, as measured by the Clock-Drawing Test, in a patient with chronic, intractable hemispatial neglect following perispinal etanercept administration.

Improvement in cognitive function within minutes after perispinal etanercept in patients with Alzheimer's disease was the initial clinical evidence suggesting the rapid synaptic and brain network effects of perispinal etanercept \[[@CR6]\]. Subsequently, rapid improvement in neurological function after perispinal etanercept was reported in patients with multiple additional chronic brain disorders \[[@CR6]--[@CR10], [@CR14], [@CR16]\]. Rapid improvement in neglect of the left hemispace in the Clock-Drawing Test after perispinal etanercept is consistent with these previous clinical observations; the growing body of evidence documenting the existence of chronic brain inflammation after stroke and traumatic brain injury; independent evidence that neuroinflammation is associated with a reduction in functional connectivity in the brain; the rapid synaptic and neuronal effects produced by TNF in animal studies; and improvement in stroke outcomes after receiving etanercept in multiple animal models \[[@CR6]--[@CR12], [@CR14], [@CR16], [@CR21]--[@CR24]\]. Rapid improvement of hemispatial neglect after perispinal etanercept is also consistent with the concept that hemispatial neglect reflects brain network dysfunction and a disturbance in functional connectivity that is mediated by TNF.

This patient's pain description, along with the anatomic distribution of sensory loss and cold allodynia, with no other apparent cause of neuropathic pain, was pathognomonic of central post-stroke pain \[[@CR25]\].

The existence of a therapeutic effect is supported by multiple factors, including:the rapid neurological improvement in this patient who had chronic, intractable post-stroke neurological dysfunction that had been present for 16 years;the pattern and immediacy of improvement;the replication of the same distinctive pattern of improvement in clock drawing (immediate resolution of neglect of the left hemispace) in multiple post-stroke patients;the concurrent improvement in chronic, central post-stroke pain, in addition to improvement in hemispatial neglect, immediately following perispinal etanercept injection;the known role of TNF in modulating synaptic function, including synaptic strength and synaptic scaling;the known association of inflammation and decreased functional connectivity in the brain in other brain disorders.

The striking pattern of immediate improvement in clock drawing documented in this patient with chronic, previously intractable, central post-stroke pain, chronic post-stroke fatigue, and left hemispatial neglect is most consistent with rapid restoration of brain functional connectivity. This evidence suggests hemispatial neglect may be caused by TNF-mediated network dysfunction and impairment in functional connectivity that remains reversible, even years after stroke. This evidence also suggests that central post-stroke pain may be mediated by TNF.

Functional magnetic resonance scanning and positron emission tomographic studies to image brain functional connectivity and neuroinflammation when studying therapeutics that target neuroinflammation in basic science studies and clinical trials may add to our understanding of the nature of chronic post-stroke neurological dysfunction.
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Informed consent was obtained for the treatment of this patient. Treatment was performed as part of our usual practice of medicine and was not performed as part of a research study. Written consent was obtained for the publication of this case report.
